# Verdict: chondroblastoma.md (Wave 2, adversarial review)

## 1. DOSE LEAK
None. Only digit occurrences in the file are gene names (`H3F3A`/`H3F3B`, the "3" in each) and
"12th ed." in the DeVita citation — no mg, mg/m2, AUC, Gy, %, cycle number, or q-schedule anywhere.

## 2. UNGROUNDED CLAIMS
- DeVita grounding: **zero** clinical lines. `grep -ni chondroblastoma devita.txt` returns exactly
  one hit — a bibliographic reference-list entry ("...mutations define chondroblastoma and giant
  cell tumor of bone. Nat Genet") — not clinical management text. The sidecar discloses this
  correctly and does not misattribute any claim to DeVita.
- All treatment content (curettage + bone graft/cement, local adjuvants — burring/cryotherapy/
  phenol, RFA for small favorable-location lesions, wide resection only for recurrent/destructive
  disease, no chemo/RT role, surveillance imaging, referral triggers including clear cell
  chondrosarcoma mimicry and pulmonary implants) is standard orthopaedic-oncology teaching, not
  drug/trial/statistic-specific, and matches the existing KB reference entry per the draft agent's
  own note. Nothing rises to the level of a specific regimen, trial name, or numeric statistic
  needing independent verification.
- One soft spot: the closing "Sources" line invokes "NCCN Guidelines (general soft tissue and bone
  sarcoma framework)" for the local-control-over-systemic-therapy principle. NCCN's bone cancer
  guideline is oriented at malignant bone tumors (osteosarcoma/chondrosarcoma/Ewing/GCT) and does
  not have a dedicated chondroblastoma section either — this attribution is unverified/loose, though
  it's only backing an uncontroversial, non-numeric principle rather than a specific regimen. Minor,
  not a fabrication risk, but R1 should treat "NCCN Guidelines" here as approximate/generic rather
  than a pinned source.

## 3. CITATION
Present. Closing paragraph names "DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of
Oncology, 12th ed." by name only (no page numbers), and honestly states DeVita has no dedicated
clinical text for this disease — an accurate, non-fabricated disclosure rather than a fake pinned
citation.

## 4. VERDICT: CLEAN (ready for R1)
No dose leak, no fabricated regimens/trials/statistics, honest disclosure of DeVita's silence on
this benign tumor, content consistent with uncontroversial orthopaedic-oncology standard of care.
Only note for R1: treat the "NCCN Guidelines" attribution as generic/approximate, not a verified
pinned source, since NCCN has no chondroblastoma-specific section either.
